# Rondo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rondo-therapeutics

- Industry: Biotechnology
- Headquarters: Hayward, US
- Website: www.rondotx.com
- Total disclosed funding: $17M
- Latest round: Series A (Feb 24, 2022)
- Investors on record: 5

## About

Based in California, US, and founded in 2020 by its CEO Shelley Force Aldred and CSO Nathan Trinklein, Rondo Therapeutics, Inc. operates as a biopharmaceutical company that develops immuno-oncology therapy to treat patients with cancer. In March 2022, Rondo Therapeutics, Inc. raised USD 67 million in series A funding co-led by new investors Canaan Partners and Red Tree Venture Capital, with participation from other new investors Johnson & Johnson Innovation, Novo Holdings, and SV Health Investors.

Rondo Therapeutics, Inc. creates bispecific antibodies that safely engage the immune system to initiate and sustain a robust anti-tumor response and overcome the suppressive tumor microenvironment. It focuses on addressing the significant unmet need for novel immunotherapy approaches capable of treating solid tumors. 

The company will use the series A funding to support the development of a new class of immune-stimulatory bispecific antibody therapeutics designed to address solid tumors.

## Funding rounds

- Series A, Feb 24, 2022, $17M — Canaan Partners, SV Health Investors, Johnson & Johnson Innovation, Novo Holdings, Red Tree Venture Capital

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Novo Holdings — Series A
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series A